Valparin

Main information

  • Trade name:
  • Valparin X500 Tablet
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Valparin X500 Tablet
    Malaysia
  • Language:
  • English

Other information

Status

  • Source:
  • NPRA - National Pharmaceutical Regulatory Agency - Bahagian Regulatori Farmasi Negara
  • Authorization number:
  • MAL05121152
  • Last update:
  • 28-05-2018

Patient Information leaflet

VALPARIN XR 500 TABLET

Sodium valproate (500mg)

1

Consumer Medication Information leaflet (RiMUP)

What is in this leaflet

What is Valparin XR used for

How Valparin XR works

Before you use Valparin XR

How to use Valparin XR

While you are using it

Side effects

Storage and disposal of Valparin

Product description

Manufacturer

Product

Registration Holder

Date of revision

What Valparin XR is used for

Valparin XR is used for:

treatment

generalised

partial

epilepsy,

particularly

with

the following patterns of seizures:

Absence

(short

period

“blanking out” or staring into

space).

Myoclonic

(brief

shock-like

jerks of a muscle).

Atonic (abrupt loss of muscle

tone).

Tonic-clonic

(loss

consciousness

violent

muscle contractions)

Mixed seizures.

Partial epilepsy:

Simple

(not

affecting

awareness or memory).

Complex seizures.

Secondary generalised seizures

(start in one area and spread to

both sides of the brain).

Specific

syndromes

(West,

Lennox-Gastaut).

How Valparin XR works

Valparin

contains

sodium

valproate.

belongs

group

medicines

called

anti-convulsants

anti-epileptic agents. These medicines

are thought to work by controlling brain

chemicals which send signals to nerves

so that seizures do not happen.

Before you use Valparin XR

When you must not use it

Do not take Valparin XR:

If you are allergic (hypersensitive)

to sodium valproate or any of the

other ingredients.

If you are having liver problems or

you or your family have a history

of liver problems.

having

rare

illness

called porphyria (a rare hereditary

disease in which the blood pigment

hemoglobin

abnormally

metabolized).

Pregnancy and lactation

If

you

are

a

female

patient

of

childbearing age, make sure that you

talk to your doctor about the risks

associated with taking Valparin XR

during pregnancy.

Tell your doctor if you are pregnant

or intend to become pregnant.

Like

most

medicines

this

kind,

Sodium Valproate Valparin XR may

affect your developing baby if taken in

the first trimester of pregnancy, as it is

suspected of causing an increased risk

of malformations in the exposed foetus.

However,

stop

taking

your

medication unless your doctor says so

as there are risks to the mother and

child from uncontrolled epilepsy.

Your doctor may want to adapt your

treatment

and/or

prescribe

dietary

supplements of folate.

Your doctor will discuss the risks and

benefits of taking it if you are pregnant.

Tell

your

doctor

if

you

are

breastfeeding

or

planning

to

breastfeed.

Medicines

used

treatment

epilepsy, including Valparin XR, pass

into

breast

milk.

Your

doctor

will

discuss the risks and benefits of taking

it if you are breastfeeding or planning

to breastfeed.

Before you start use it

Tell your doctor if you have or have

had any medical conditions, especially

the following:

Liver problems (liver insufficiency,

liver damage).

Kidney problems

Have

have

depression,

mood

problems,

suicidal

thoughts or behavior.

Systemic

lupus

erythematosus

(SLE), an autoimmune disease

Symptoms of pancreatitis such as

abdominal pain, nausea, vomiting

or anorexia.

Taking other medicines

Tell your doctor if you are taking any

other medicines, including any that you

without

prescription

from

pharmacy, supermarket or health food

shop.

Some medicines and sodium valproate

may interfere with each other. These

include:

Other

medicines

used

treat

epilepsy

e.g.

phenobarbitone,

primidone,

phenytoin,

carbamazepine,

felbamate

lamotrigine.

Carbapenem

agents

(antibiotics

used to treat bacterial infections)

such

imipenem,

meropenem,

erythromycin.

combination of Valparin XR and

carbapenems

should

avoided

because it may decrease the effect

of your medicine.

Colestyramine used to lower blood

fat (cholesterol) levels.

Medicines used to treat depression

e.g. monoamine oxidase inhibitors

(MAOIs).

Benzodiazepines

(medicines

used

as sedatives or to treat anxiety).

Medicines

used

prevents

clotting (such as warfarin).

Some

medicines

used

prevention

treatment

malaria

such

mefloquine

chloroquine.

Cimetidine

used

stomach

ulcers.

Zidovudine (an antiviral agent).

Aspirin.

How to use Valparin XR

How much to use

Monotherapy

Adults:

The starting dose is 600mg daily.

Your doctor will gradually increase

this dose by 200mg every 3 days

depending on your condition.

usual

dose

generally

between 1000mg and 2000mg (20-

30mg

kilogram

body

weight) each day.

This may be increased to 2500mg

each

depending

your

illness.

VALPARIN XR 500 TABLETS

Sodium valproate (500mg)

2

Consumer Medication Information leaflet (RiMUP)

Children over 20 kilograms:

The starting dose should be 400mg

daily. Your doctor should increase

this dose depending on your child’s

Illness.

usual

dose

then

between

20mg and 30mg for each kilogram

of body weight each day.

This may be further increased to

35mg for each kilogram of body

weight each day depending on your

child’s illness.

Follow all directions given to you by

your doctor and pharmacist carefully.

They may differ from the information

contained

this

leaflet.

This

depend on your age, your condition and

whether or not you are taking any other

medicines. If you do not understand the

instructions

label,

your

doctor or pharmacist for help.

When to use it

Valparin XR 500 may be given once or

twice

daily.

tablet

should

swallowed whole and not crushed or

chewed.

How long to use it

Continue

taking

Valparin

long as your doctor recommends.

If you forget to use it

Take the missed dose as soon as you

remember. If it is almost time for your

next dose, wait until then to take the

medicine and skip the missed dose. Do

not take a double dose to make up for

the missed dose.

If you use too much (overdose)

If you take too much Valparin XR, call

your

doctor

poison

control

center

right away, or get emergency treatment

at nearest hospital as soon as possible.

If you take too much Valparin XR, the

following effect may happen: nausea,

vomiting,

dizziness,

coma,

weak

muscles and poor reflexes, pupils of the

eye become smaller, breathing problem,

fits (seizure), brain oedema, increased

intracranial

pressure

(pressure

inside

the skull).

While you are using it

Things you must do

Take

your

medicine

exactly

your doctor has told you.

Tell all the doctors, dentists and

pharmacists treating you that you

are taking Valparin XR.

Tell

your

doctor

immediately

you become pregnant while taking

this medication.

Women taking Valparin XR during

pregnancy have a higher risk than

other women of having a child with

an abnormality (like Head and face

deformities including cleft palate (a

depression

lip),

abnormality

spinal

cord

called ‘Spina bifida’).

Things you must not do

Do not stop taking the medicine

unless advised by your doctor.

take

medicines

without consulting your doctor.

Do not give Valparin XR to anyone

else, even if they have the same

symptoms or condition as you..

Things to be careful of

This

medicine

produce

suicidal

thoughts or behavior. If this happens

contact your doctor immediately.

Driving and using machines

This medicine may affect your ability

to drive or use machines. If the tablets

make you feel sick or sleepy do not

drive or use machines and contact your

doctor immediately.

Side effects

Like all medicines, Valparin XR can

cause

side

effects,

although

everybody gets them.

Visit

your

doctor

pharmacist

immediately if you experience any side

effects after taking this medicine:

Increased

liver

enzymes,

liver

dysfunction, severe liver damage,

including liver failure.

Nausea.

Pancreatitis

(inflammation

pancreas).

Allergic

reactions

(ranging

from

rash to hypersensitivity reactions).

Lethargy and confusion, deep loss

consciousness

(coma),

convulsions.

Loss of memory (dementia).

Hair loss.

Feeling shaky (tremor),

Sleepy.

Thrombocytopenia

(decrease

platelets in blood).

Anaemia

(decrease

blood

cell), leucopenia (decrease in white

blood

cell)

pancytopenia

(decrease in blood cells).

Blood clotting problems.

Redness of skin.

Toxic epidermal necrolysis (Severe

blistering rash where layers of the

skin may peel off to leave large

areas of raw exposed skin over the

body).

Stevens-Johnson

syndrome

(Blistering or bleeding of the skin

around the lips, eyes, mouth, nose

and genitals).

Erythema multiforme (skin rash or

skin lesions with a pink/red ring

and a pale centre which may be

itchy, scaly or filled with fluid. The

rash may appear especially on the

palms or soles of your feet).

Peripheral oedema.

Amenorrhoea

(absence

menstrual

period)

irregular

periods.

Reversible

Fanconi’s

syndrome

(kidney malfunction giving rise to

glycosuria (excess of sugar in the

urine),

aminoaciduria

(abnormal

amount

amino

acids

urine),

phosphaturia

(presence

excessive

quantity

phosphates

urine),

uricosuria

(presence

excessive

amounts of uric acid in the urine)).

Tell your doctor immediately, or go to

Accident

Emergency

your

nearest hospital if you notice any of the

following side effects.

The following side effects may be signs

of problems with your liver or pancreas

such as:

Asthenia (weakness).

Anorexia (eating disorder).

Lethargy.

Drowsiness.

Vomiting.

Abdominal pain.

Nausea.

VALPARIN XR 500 TABLETS

Sodium valproate (500mg)

3

Consumer Medication Information leaflet (RiMUP)

This

complete

list

side

effects.

Contact

your

doctor

pharmacist if you experience any side

effects.

If any of the side effects gets serious, or

if you notice any side effects not listed

in this leaflet, please tell your doctor or

pharmacist.

report

side

effects

adverse drug reactions directly to the

National

Centre

Adverse

Drug

Reaction Monitoring by calling Tel: 03-

78835550,

visiting

website

portal.bpfk.gov.my

(Consumers

Reporting).

Storage and disposal of Valparin XR

Storage

Keep in a dry place at a temperature not

exceeding 30

Disposal

Medicines should not be disposed of

via wastewater or household waste. Ask

your

pharmacist

dispose

medicines

longer

required.

These

measures

will

help

protect

environment.

Product description

What it looks like

White,

oblong

shaped

film

coated

tablets with breakline on both sides.

Ingredient

Active ingredient(s)

Sodium Valproate.

Valproic acid.

Inactive ingredient(s)

Colloidal silicon dioxide.

Hydroxypropylmethyl cellulose.

Ethyl cellulose.

Hydrated silica.

Saccharin sodium.

Glycerin.

Titanium dioxide.

Eudragit E 100.

Eudragit NE 30D.

Polyethylene glycol.

Talc.

Methanol.

MAL number:

MAL05121152A

Manufacturer

TORRENT PHARMACEUTICALS

LTD.

Indrad 382 721, District: Mehsana,

INDIA.

Product Registration Holder

Laboratories

Torrent

(Malaysia)

Sdn.

Bhd.

Suite E-08-08 Plaza Mont Kiara,

No. 2 Jalan Kiara Mont Kiara,

50480 Kuala Lumpur,

Malaysia.

Date of revision

22/02/2016

Serial Number

BPFK(R4/1)190216/00051

18-9-2018

Peer review of the pesticide risk assessment of the active substance sodium hydrogen carbonate

Peer review of the pesticide risk assessment of the active substance sodium hydrogen carbonate

Published on: Fri, 14 Sep 2018 00:00:00 +0200 The conclusions of EFSA following the peer review of the initial risk assessments carried out by the competent authority of the rapporteur Member State Austria for the pesticide active substance sodium hydrogen carbonate are reported. The context of the peer review was that required by Regulation (EC) No 1107/2009 of the European Parliament and of the Council. The conclusions were reached on the basis of the evaluation of the representative use of sodium hyd...

Europe - EFSA - European Food Safety Authority Publications

7-9-2018

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Montelukast Tablets USP, 10mg 30Ct. due to Product/Label Mix-Up

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Montelukast Tablets USP, 10mg 30Ct. due to Product/Label Mix-Up

Camber Pharmaceuticals, Inc. is voluntarily recalling one single lot of Montelukast Sodium Tablets, USP 10mg, to the consumer level. This recall of one batch of Montelukast Sodium Tablets, USP 10mg, lot# MON17384 Exp. 12/31/2019, was prompted because a complaint of a sealed bottle labeled as Montelukast 10mg 30 ct found to contain 90 tablets of Losartan Potassium Tablets, USP 50mg

FDA - U.S. Food and Drug Administration

7-9-2018

SCA Pharmaceuticals LLC. Issues Voluntary Nationwide Recall of Furosemide 100 mg in 0.9% Sodium Chloride due to Presence of Precipitate

SCA Pharmaceuticals LLC. Issues Voluntary Nationwide Recall of Furosemide 100 mg in 0.9% Sodium Chloride due to Presence of Precipitate

, SCA Pharmaceuticals LLC (“SCA Pharma”) is voluntarily recalling 7 lots of the injectable product Furosemide 100 mg in 0.9% Sodium Chloride 100 mg bag to the consumer level. This product is being recalled for visible particulate matter believed to be furosemide precipitate.

FDA - U.S. Food and Drug Administration

31-8-2018

FDA announces voluntary recall of Montelukast tablets by Camber Pharmaceuticals due to incorrect drug in bottles

FDA announces voluntary recall of Montelukast tablets by Camber Pharmaceuticals due to incorrect drug in bottles

FDA is warning the public about a voluntary recall of one lot of montelukast sodium tablets made by Camber Pharmaceuticals due to incorrect drug in bottles

FDA - U.S. Food and Drug Administration

29-8-2018

SGLT2(sodium-glucose cotransporter-2) Inhibitors for Diabetes: Drug Safety Communication - Regarding Rare Occurrences of a Serious Infection of the Genital Area

SGLT2(sodium-glucose cotransporter-2) Inhibitors for Diabetes: Drug Safety Communication - Regarding Rare Occurrences of a Serious Infection of the Genital Area

Requiring a new warning about this risk to be added to the prescribing information of all SGLT2 inhibitors and to the patient Medication Guide.

FDA - U.S. Food and Drug Administration

31-7-2018

AuroMedics Pharma LLC Issues Voluntary Nationwide Recall of Piperacillin and Tazobactam for Injection 3.375 grams per vial, Due to Presence of Particulates Identified as Glass and Silicone Material

AuroMedics Pharma LLC Issues Voluntary Nationwide Recall of Piperacillin and Tazobactam for Injection 3.375 grams per vial, Due to Presence of Particulates Identified as Glass and Silicone Material

East Windsor, New Jersey, AuroMedics Pharma LLC is voluntarily recalling two lots of Piperacillin and Tazobactam for injection, USP 3.375 g (Piperacillin Sodium equivalent to 3 g of Piperacillin USP and Tazobactam Sodium equivalent to 0.375 g of Tazobactam USP. Each vial contains 7.05 mEq (162 mg) of Sodium) in a Single-Dose vial, to the hospital level. One vial from lot# PP0317012-A was found to contain particulate matter, identified as glass within the vial and another vial from lot# PP0317059-A was fo...

FDA - U.S. Food and Drug Administration

18-7-2018

Sodium glucose co-transporter 2 inhibitors

Sodium glucose co-transporter 2 inhibitors

Safety advisory - diabetic ketoacidosis and surgical procedures

Therapeutic Goods Administration - Australia

25-5-2018

Orphan designation:  Treprostinil sodium,  for the: Treatment of chronic thromboembolic pulmonary hypertension

Orphan designation: Treprostinil sodium, for the: Treatment of chronic thromboembolic pulmonary hypertension

On 8 February 2013, orphan designation (EU/3/13/1103) was granted by the European Commission to SciPharm S.a.r.L, Luxembourg, for treprostinil sodium for the treatment of chronic thromboembolic pulmonary hypertension.

Europe - EMA - European Medicines Agency

17-10-2014

PRAC recommends strengthening the restrictions on the use of valproate in women and girls

PRAC recommends strengthening the restrictions on the use of valproate in women and girls

The EMA’s Pharmacovigilance and Risk Assessment Committee (PRAC) recommends strengthening the restrictions on the use of the antiepileptic valproate due to the risk of malformations and developmental problems in children exposed to valproate in the womb.

Danish Medicines Agency

27-8-2018

Arixtra (Aspen Pharma Trading Limited)

Arixtra (Aspen Pharma Trading Limited)

Arixtra (Active substance: Fondaparinux sodium) - PSUSA - Modification - Commission Decision (2018)5708 of Mon, 27 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/403/PSUSA/1467-201712

Europe -DG Health and Food Safety

3-8-2018

Sodium oxybate

Sodium oxybate

Sodium oxybate (Active substance: Sodium oxybate) - Centralised - Art 28 - (PSUR - Commission Decision (2018)5381 of Fri, 03 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/10612/201710

Europe -DG Health and Food Safety

2-8-2018

EU/3/18/2043 (Dr Ulrich Granzer)

EU/3/18/2043 (Dr Ulrich Granzer)

EU/3/18/2043 (Active substance: Combination of carboplatin and sodium valproate) - Orphan designation - Commission Decision (2018)5275 of Thu, 02 Aug 2018 European Medicines Agency (EMA) procedure number: EMA/OD/036/18

Europe -DG Health and Food Safety

11-7-2018

Fosavance (Merck Sharp and Dohme B.V.)

Fosavance (Merck Sharp and Dohme B.V.)

Fosavance (Active substance: Alendronate Sodium / Colecalciferol) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)4518 of Wed, 11 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/619/T/42

Europe -DG Health and Food Safety

10-7-2018

Adrovance (Merck Sharp and Dohme B.V.)

Adrovance (Merck Sharp and Dohme B.V.)

Adrovance (Active substance: Alendronate sodium / Colecalciferol) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)4477 of Tue, 10 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/759/T/39

Europe -DG Health and Food Safety

10-7-2018

Ammonaps (Swedish Orphan Biovitrum International AB)

Ammonaps (Swedish Orphan Biovitrum International AB)

Ammonaps (Active substance: Sodium phenylbutyrate) - Centralised - Yearly update - Commission Decision (2018)4483 of Tue, 10 Jul 2018

Europe -DG Health and Food Safety

5-7-2018

Withdrawn application:  Prohippur, sodium benzoate, Initial authorisation

Withdrawn application: Prohippur, sodium benzoate, Initial authorisation

Europe - EMA - European Medicines Agency

19-6-2018

Xyrem (UCB Pharma S.A.)

Xyrem (UCB Pharma S.A.)

Xyrem (Active substance: Sodium oxybate) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3912 of Tue, 19 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/593/T/74

Europe -DG Health and Food Safety

1-6-2018

Valproate

Valproate

Valproate (Active substance: medicinal products containing substances related to valproate (sodium valproate, valproic acid, valproate semisodium, valpromide, valproate magnesium)) - Community Referrals - Art 31 - Commission Decision (2018)3623 of Fri, 01 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/A-31/1454

Europe -DG Health and Food Safety

28-3-2018

EU/3/17/1876 (FGK Representative Service GmbH)

EU/3/17/1876 (FGK Representative Service GmbH)

EU/3/17/1876 (Active substance: Sodium (1R,3R,4R,5S)-3-({2-N-acetylamino-2-deoxy-3-O-[(1S)-1-carboxylato-2-cyclohexylethyl]-beta-D-galactopyranosyl}oxy)-4-({6-deoxy-alpha-L-galactopyranosyl}oxy)-5-ethyl-cyclohexan-1-yl-(38-oxo-2,5,8,11,14,17,20,23,26,29,32,35-dodecaoxa-39-azahentetracontan-41-yl)carboxamide) - Transfer of orphan designation - Commission Decision (2018)2011 of Wed, 28 Mar 2018 European Medicines Agency (EMA) procedure number: EMA/OD/010/17/T/01

Europe -DG Health and Food Safety

21-3-2018

EU/3/16/1711 (Akcea Therapeutics UK Ltd)

EU/3/16/1711 (Akcea Therapeutics UK Ltd)

EU/3/16/1711 (Active substance: Volanesorsen sodium) - Transfer of orphan designation - Commission Decision (2018)1822 of Wed, 21 Mar 2018 European Medicines Agency (EMA) procedure number: EMA/OD/082/16/T/01

Europe -DG Health and Food Safety